Inhibitors of the BCR–ABL1 fusion protein have improved outcomes in Philadelphia-chromosome-positive (Ph+) leukaemias, but acquired resistance can limit drug responses. Now, axitinib, a VEGFR inhibitor approved for second-line therapy of renal cell carcinoma, has been identified as an inhibitor of...
(女,43岁) 急性淋巴细胞白血症(BCL_ABL P210阳性 )治愈率多高, 医生回复 周其锋 血液内科 主任医师 三级甲等 淄博市第一医院 问题分析:病人家属咨询:急性淋巴细胞白血症(BCL_ABLP210阳性)治愈率多高。家属未提供病历资料。 指导建议:这个要根据病人具体情况,特别是病人两个疗程化疗后,是否取得骨髓完全缓解,...
There was no difference in tumor latency in young mice infected; however, following ABL-MYC infection, aged Bcl-X L mice demonstrated a median survival of 9 weeks, while littermate control mice demonstrated a median survival of 19 weeks. Interestingly, while both littermate control and Bcl-X ...
Martin, SJ, Reutelingsperger, CPM, McGahon, AJ, Rader, JA, van Schie, RCAA, LaFace, DM & Green, DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med...
Dasatinib(达沙替尼)是非受体酪氨酸激酶 Abl 和 Src 以及 Src 家族其他成员的有效抑制剂。 它在亚纳摩尔浓度下有效,抑制 Src、Abl 和 Lck,IC50 值分别为 0.05、0.5 和 0.4 nM。在纳摩尔浓度下,达沙替尼还阻断其他几种受体和非受体酪氨酸激酶的活性, 加上耐药突变体。 由于这些活性,达沙替尼对以这些激酶水平...
百度试题 结果1 题目(题型三)已知lala+b1b+lcl=-1,试求abl ab+bcbcl+caca+abcabc的值. 相关知识点: 试题来源: 解析 解:因为lal-|||-a+b1-|||-b+lcl=-1,所以a,b,c中有两个负数、一个正数. 反馈 收藏
The GLG1 protein is a transmembrane protein known also as MG-160, ESL-1, and CFR-1. Irregularities in the GLG1 functions affect the adhesion, mobility, and migration of cells. In this study, the interaction between the GLG1 protein and the Bcr-Abl oncoprotein is shown for the first ...
(2012) DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia. Br J Haematol 159: 373-376.Leo E, Mancini M, Aluigi M, et al. DNA hypermethylation pro- motes the low expression of pro-apoptotic BCL2L11 ...
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.doi:10.1038/nature09883Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on ...